Last updated on February 2018

Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy

Brief description of study

This study aims to verify superiority of pemetrexed maintenance to observation for patient without disease progression after 1 st line cisplatin-based chemotherapy.

Detailed Study Description

Patients with unresectable locally advanced, recurrent, or metastatic urothelial carcinoma of bladder, ureter, or renal pelvis who do not experience disease progression after 4 to 6 cycles of 1 st line chemotherapy administration.

After completion of 4-6 cycles, patients without disease progression on CT which is taken within 3 weeks after administration of the last chemotherapy will be randomized within 4 weeks after administration of the last chemotherapy to assign either maintenance group or observation group.

Pemetrexed 500 mg/m 2 mixed in normal saline 100 mL as a 10 minute IV infusion on day 1 of each 21 day cycle, with vitamin supplementation (folic acid 1000g daily orally from 7 days prior to treatment initiation and vitamin B12 1000 g IM 7 days prior to treatment initiation and then every 3 cycles). Thereafter, vitamin B12 can be injected on the same day of pemetrexed infusion. Dexamethasone 4 mg orally twice daily for 3 days beginning the day before treatment to minimize cutaneous reactions.

Treatment continues until occurrence of disease progression or intolerable toxicities upto maximum of 16 cycles.

Clinical Study Identifier: NCT03193788

Find a site near you

Start Over

Yonsei Cancer Center

Seoul, Korea, Republic of
  Connect »

Fatima Hospital

Daegu, Korea, Republic of
  Connect »

Chungnam University Hospital

Daejeon, Korea, Republic of
  Connect »

Gil Medical Center

Incheon, Korea, Republic of
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »